Rare Case of FUS, Tau Coexistence in Sporadic ALS Suggests Potential Biological Interaction
Tau and FUS proteins may contribute to a cellular process common to both amyotrophic lateral sclerosis (ALS) and…
Articles by Margarida Azevedo, MSc
ProMIS Moving into 2nd Phase of Work on Antibody Treatment for ALS
ProMIS Neurosciences announced that it is moving toward selecting antibodies — from the many identified in earlier work — that…
Potential Gene Therapy for Familial ALS Named Orphan Drug by EMA
A gene therapy that might treat familial amyotrophic lateral sclerosis (ALS), an inherited form of the disease, was recently…
Clinigen, Mitsubishi Tanabe Announce Early Access Program in Europe for ALS Therapy Radicava
Clinigen Group recently partnered with Mitsubishi Tanabe Pharma Corporation to launch an early access program in Europe for…
MDA Grants Include Research Projects for ALS and Other Diseases
The Muscular Dsytrophy Association (MDA) awarded 13 new grants totaling $2.6 million to find treatments for neuromuscular disorders,…
Muscular Dystrophy Association, ALS ONE Form Partnership to Find New ALS Biomarkers
The Muscular Dystrophy Association (MDA) recently awarded the Massachusetts General Hospital (MGH) a $750,000 human clinical trial grant…
ALS Association, Cytokinetics Renew Partnership in Fight Against ALS
The ALS Association and Cytokinetics will continue to collaborate in the fight against amyotrophic lateral sclerosis (ALS) through a series of…
New Company, MAGiQ, Aims to Develop Stem Cell Therapies for ALS and Like Diseases
A new Japanese joint venture company called MAGiQ Therapeutics — the result of a collaboration between Q Therapeutics and Reprocell — aims…
European Agency Issues Negative Opinion on Marketing Authorization for Masitinib in ALS
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the conditional marketing authorization…
Canada Accepts New Drug Submission, Grants Priority Review for Edaravone to Treat ALS
Health Canada accepted Mitsubishi Tanabe Pharma’s new drug submission (NDS) for edaravone as an intravenous treatment option for…